The process took 4 weeks. They do not pay as much and there is very little status or mobility. I interviewed at Flatiron Health (New York, NY) in Jan 2021. Applied online with resume and cover letter. Data quality was the focus of a presentation by Emily Castellanos, M.D., associate medical director for research oncology at Flatiron Health. I applied online. Familiar with all aspects of how cancer is treated, from diagnosis to recovery, and fluent in cancer terminology; Knowledge and experience with AJCC staging This will replace the current featured interview for this targeted profile. The process took 1 week. It's the actual abstracting tests that determine your actual continuing employment that are a pain. The case scenarios were extremely difficult meaning if you have ACTUAL cancer registry experience you will realize that you have to go against what you've been taught and follow what they want you to do. The process took 2 weeks. Received an email with a link to an assessment. I have 3+ years of cancer registry experience and excellent quality and still did not pass the case scenarios. I applied through an employee referral. A free inside look at company reviews and salaries posted anonymously by employees. The interviewer told me more about the company, what their goals were, and what my position as an abstractor would entail. I work in this field and there is no way I didn't pass the exam, unless there was something completely amiss. Gemcitabine and nab-paclitaxel in older adults with metastatic pancreatic cancer: are two doses per cycle enough? Average salary: $55,955. Easy application + a few tasks to prove I could type and knew oncology. The process took 1+ week. A career at Flatiron is a chance to work with everyone involved in the future of cancer — all under one roof. The Ultimate Job Interview Preparation Guide. I wish the process was more transparent. Here’s Exactly What to Write to Get Top Dollar, Quality Information Specialist Inter­views, How To Follow Up After an Interview (With Templates! However, Flatiron’s abstractors are prohibited from simultaneously working for Flatiron customers. Jobs. Apply for this job I interviewed at Flatiron Health (United States). Keyboarding skills and experience with healthcare software is usually required. Got through the technical test and the medical records review. They may also identify record deficiencies and enter results into a system. Learn about the interview process, employee benefits, company culture and more on Indeed. I had a quick phone screen and an automated codility assessment, then a technical video interview. Watch the Abstractor Training Webinars Part 1 and Part 2. Review the Coding Instructions located as a download in the Patient Management Tool (PMT). Glassdoor will not work properly unless browser cookie support is enabled. I felt that they intentionally tried to trick you in the medical records by the progress notes saying one thing vs the pathology report. I applied online. American Society of Hematology Annual Meeting, Multidisciplinary Head and Neck Cancers Symposium, International Conference on Malignancies in HIV/AIDS, Annual Metastatic Breast Cancer Conference, International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), International Conference on Malignant Lymphoma, Congress of the European Hematology Association, Machine Learning for Health (ML4H) Workshop, Congress of the European Association of Dermato Oncology, Biennial Meeting of the International Gynecologic Cancer Society, ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics, American Association for Cancer Research Annual Meeting, ASCO-SITC Clinical Immuno-Oncology Symposium, ESMO World Congress on Gastrointestinal Cancer, European Society for Medical Oncology ASIA, Meeting of the Canadian Urological Association, Wang, X, Adamson, BJS, Tan, K, Baxi, SS, Briggs, A, Ramsey, SD, Hooley, IJ, Maignan, K, Jacob, A, Medina, A, Benderoff, L, Chen, R, Huntington, SF, Liang, Q, Zhang, Q, Rosic, A, Bowser, B, Tharani, S, Brake, SD, Magee, K, Parrinello, CM, Baxi, SS, Mathur, R, Barata, P, Tan, K, Pini, M, Magee, K, Baxi, SS, Coombs, L, Orlando, A, Adamson, BJS, Griffith, SD, Lakhtakia, S, Rich, A, Shaw, P, Wang, X, Miksad, RA, Mooney, K, Tan, K, Segal, BD, Bryan, J, Curtis, MD, Nussbaum, NC, Miksad, RA, Samant, MK, Sarkar, S, Torres, AZ, Stasiw, A, Falk, S, Garapati, S, Sridharma, S, Mendelsohn, D, Lakhtakia, S, Rech, A, Oldridge, D, Adamson, BJS, Chen, R, Zhang, Q, Gossai, A, Monroe, S, Nussbaum, NC, Parrinello, CM, Chaudhary, N, Luhn, P, Jansen, G, Metcalfe, C, Hafner, M, Drakaki, A, Dhillon, PK, Wakelee, H, Chui, S, Shim, J, Kent, M, Degaonkar, V, Hoang, T, McNally, V, Luhn, P, Gutzmer, R, Papillon-Cavanagh, S, Gao, C, Han, GC, Walsh, AM, Fernando, TM, Piskol, R, Bainer, R, Sokol, ES, Trabucco, SE, Zhang, Q, Trinh, H, Maund, SL, Kschonsak, M, Chaudhuri, S, Modrusan, Z, Januario, T, Modrusan, Z, Yauch, RL, Snow, T, Swaminathan, A, Snider, J, Schrock, AB, Li, G, Alexander, BM, Singal, G, Castellanos, EH, McCusker, M, Antonarakis, ES, Madison, RW, Snider, J, Snow, T, Sokol, ES, Chung, JH, McCusker, M, Singal, G, Alexander, BM, Castellanos, EH, Venstrom, JM, Schrock, AB, Ross, JS, Kirshner, J, Cohn, K, Dunder, Steven, Donahue, K, Richey, MM, Larson, PD, Sutton, LM, Siu, E, Donegan, J, Chen, Z, Nightingale, C, Hamrick, HJ, Doroshow, D, Wei, W, Zugazagoitia, J, Robbins, C, Gupta, S, Adamson, BJS, Rimm, D, Blakely, J, Gordon, L, Schwartzberg, L, Gutman, J, Adamson, BJS, Bourla, AB, Meropol, NJ, Ramsey, SD, Green, RJ, Lu, MW, Walia, G, Schulze, K, Doral, MY, Maund, SL, Gaffey, S, Cabili, MN, Bourla, AB, Green, RJ, Santos, EC, Herbst, RS, Chiang, AC, Schwartzberg, L, Riaz, F, Gan, G, Li, F, Davidoff, AJ, Adelson, KB, Presley, CJ, Adamson, BJS, Shaw, P, Parikh, RB, Mamtani, R, Gross, CP, Ou, SI, Madison, RW, Snow, T, Snider, J, McCusker, M, Singal, G, Alexander, BM, Venstrom, JM, Castellanos, EH, Schrock, AB, Yang, F, Zhang, J, O'Neill, TJ, Sharma, V, Prime, M, Swami, U, Sinnott, J, Halland, B, Maughan, BL, Rathi, N, McFarland, TR, Kohli, M, Nussenzveig, S, Pal, SK, Agarwal, N, Bernicker, E, Xiao, Y, Abraham, A, Engstrom-Melnyk, J, Croix, D, Yang, B, Shah, RA, Madala, J, Allen, T, Yang, DX, Jairam, V, Park, HS, Decker, RH, Chiang, AC, Gross, CP, Yu, JB, Braithwaite, M, Nevala-Plagemann, C, Baron, K, Halland, B, Garrido-Laguna, I, Pappas, LM, Moser, JC, Swami, U, Halland, B, Maughan, BL, Nussenzveig, S, Esther, J, Kessel, A, Pal, SK, Grivas, P, Agarwal, N, Marmarelis, ME, Hwang, W-T, Yang, Y-X, Ciunci, C, Singh, A, Aggarwal, C, Cohen, RB, Langer, CJ, Mamtani, R, Bauml, JM, Allen, T, Xiao, Y, Abraham, A, Redpath, S, Engstrom-Melnyk, J, Croix, D, Yang, B, Shah, RA, Madala, J, Bernicker, E, Chan, J, Meyer, L, Luhn, P, Flores, C, Bastere-Truchot, L, Downer, MK, Lin, YG, Wright, JD, Mehra, M, Vogel, M, Valluri, S, Nair, S, Schecter, J, Jagannath, S, Weisel, K, Usmani, SZ, Marar, M, Mamtani, R, Narayan, V, Parikh, RB, Koeller, J, Cockrum, P, Belanger, B, Corvino, FA, Surinach, A, Kim, GP, Gondos, A, Paz-Ares, L, Saldana, D, Thomas, M, Mascaux, C, Bubendorf, L, Barlesi, F, Arondekar, B, Bhak, R, Dersarkissian, M, Huynh, L, Wang, K, Davis, E, Wonrson, B, Duh, MS, Emens, LA, Craggs, C, Debiasi, M, Kent, M, Luhn, P, Hamilton, EP, Sireci, A, Hess, LM, Han, Y, Zhu, YE, Bhandari, NR, Martinez, R, Horn, L, Lin, HM, Padda, SK, Aggarwal, C, McCoach, CE, Zhu, Y, Yin, Y, Li, S, Feng, Z, Neal, JW, Kim, GP, Cockrum, P, Surinach, A, Koeller, J, Hernandez-Aya, LF, Burke, M, Collins, JM, Earle, D, Hamilton, M, Nordstrom, BL, Zhang, Y, Srivastava, S, Parikh, RB, Cohen, RB, Min, EJ, Wileyto, EP, Riaz, F, Gross, CP, Long, Q, Mamtani, R, Abushahin, LI, Cockrum, P, Surinach, A, Belanger, B, Simmons, D, Dersarkissian, M, Shenolikar, R, Wang, M-J, Lax, A, Muthukumar, A, Laliberté, F, Duh, MS, Moss, H, Secord, AA, Perhanidis, J, Hawkes, C, Rivera, DR, Lasiter, L, Christian, JB, Enewold, L, Espirito, JL, Hansen, E, Henk, HJ, Kushi, L, Lane, D, Natanzon, Y, Benito, RP, Rasmussen, E, Robert, NJ, Stewart, M, Sweetnam, C, Tymejczyk, O, Valice, E, Wagner, J, Zander, A, Allen, J, Chirovsky, D, Zhiwen, L, Yu, F, Baxi, SS, Chandwani, S, Joo, S, Ramakrishnan, K, Nakhoda, S, Deng, M, Iyer, P, Handorf, E, Jain, R, Meropol, NJ, Dotan, E, Cockrum, P, Surinach, A, Kim, GP, Mercer, D, Koeller, J, Miksad, RA, Baron, K, Nevala-Plagemann, C, Moser, JC, Halland, B, Wang, X, Garrido-Laguna, I, Morse, M, Meyer, A-M, Lawrance, M, Pereira, M, Mhatre, SK, Gaillard, V, Dayyani, F, O'Reilly, EM, Surinach, A, Wu, Z, Cockrum, P, O'Reilly, EM, Surinach, A, Dillon, A, Cockrum, P, Yu, KH, Dieguez, G, Surinach, A, Mercer, D, Cockrum, P, Kim, GP, Pelizzari, P, Stein, S, Snider, J, McCusker, M, Miksad, RA, Alexander, BM, Castellanos, EH, Backenroth, D, Schrock, AB, Madison, R, Carson, KR, Ali, SM, Shankaran, V, Xiao, H, Bertwistle, D, Zhang, Y, Abraham, P, Chau, I, Bazhenova, L, Jiao, X, Lokker, A, Snider, J, Castellanos, EH, Nanda, S, Fisher, V, Zong, J, Keating ,K, Fellous, M, Downer, MK, Jhaveri, K, Bardia, A, Loi, S, Kent, M, Luhn, P, Humke, EW, Carter, GC, Sheffield, KM, Gossai, A, Huang, Y, Zhu, YE, Bowman, L, Smyth, EN, Mathur, R, Cohen, AB, Baxi, SS, Rybowski, S, Chong, AL, Seidman, AD, Turner, SJ, Wang, I, Park, J, Kanakamedala, H, Lorenzo, I, Downer, MK, Luhn, P, Miles, D, Kent, M, Russell, K, O'Shaughnessy, J, Rocque, GB, Gilbert, A, Williams, CP, Nakhmani, A, Kandhare, PG, Azuero, A, Bhatia, S, Kenzik, KM, Burkard, ME, Sanglier, T, Shim, J, Liu, H, Song, C, Smitt, M, Flahavan, EM, Polito, L, Shim, J, Du Toit, YD, Do, T, Knott, A, Sanglier, T, Rozenblit, M, Pusztai, L, Adelson, KB, Mougalian, SS, DeMichele, A, Cristofanilli, M, Brufsky, A, Liu, X, Mardekian, J, McRoy, L, Layman, RM, Rugo, HS, Finn, RS, Brufsky, A, Chen, C, Mardekian, J, Liu, X, McRoy, L, Torres, M, Maignan, K, Azzam, SP, Adamson, BJS, Parrinello, CM, Foster, RB, Tromanhauser, M, Gayer, C, Gonzales, P, Maignan, K, Opong, A, Torres, AZ, Braunlin, M, Belani, R, Buchanan, J, Wheeling, JT, Kim, C, Huntington, SF, Soulos, PR, Barr, P, Jacobs, R, Lansigan, F, Odejide, OO, Schwartzberg, L, Davidoff, AJ, Gross, CP, Hooley, IJ, Parrinello, CM, Opong, A, Maignan, K, Fisher, R, Ayers, EC, Margolis, DJ, Gimotty, PA, Landsburg, DJ, Ailawadhi, S, Romanus, D, Cherepanov, D, Yin, Y, Cheng, M-R, Hari, P, Chen, R, Garapati, S, Wu, D, Ko, S, Falk, S, Dierov, D, Stasiw, A, Opong, A, Durie, BGM, Kumar, S, Usmani, SZ, Nonyane, BAS, Ammann, EA, Lam, A, Kobos, R, Maiese, EM, Facon, T, Krebs M,G, Perez, L, Surinach, A, Doebele, RC, Martina, R, Martinec, M, Riehl, T, Meropol, NJ, Wong, WB, Crane, G, Connor, S, Orfanos, P, Flahavan, EM, Patterson, K, Lee, D, Smare, C, Dave, K, Juarez-Garcia, A, Schoenherr, N, Abraham, P, Penrod, JR, Camidge, DR, Yuan, Y, von der Hyde, E, Welslau, M, Gauler, T, Rothni,e K, Waldenberger, D, Deitz, A, Hooley, IJ, Cohen, AB, Gross, CP, Williams, ER, Adamson, BJS, Adamson, BJS, Cohen, AB, Cheever, MA, Hooley, IJ, Williams, ER, Tymejczyk, O, Peeples, M, Hernandez, M, Meropol, NJ, Uldrick, TS, Moser, JC, Wei, G, Colonna, SV, Grossman, KF, Patel, SB, Hyngstrom, JR, Torres, M, Liu, X, Mardekian, J, McRoy, L, Krebs, MG, Perez, L, Surinach, A, Doebele, RC, Martina, R, Martinec, M, Riehl, T, Meropol, NJ, Wong, WB, Crane, G, Cohen, AB, Neri, B, Adamson, BJS, Scanlon, CM, Gross, CP, Meropol, NJ, Miksad, RA, Krebs, MG, Polito, L, Smoljanovic, V, Trinh, H, Crane, G, Layman, RM, Liu, X, Mardekian, J, McRoy, L, Sanglier, T, Fabi, A, Flores, C, Flahavan, EM, Lindegger, N, Montemurro, F, Jiao, X, Lokker, A, Snider, J, Castellanos, EH, Nanda, S, Fisher, V, Zong, J, Keating, K, Fellous, M, Torres, AZ, Mathur, R, Maignan, K, Tucker, MG, Ciofalo, KJ, Khozin, S, Carson, KR, Backenroth D, Shao C, Li G, Huang L,Pruitt SK, Castellanos EH, Frampton GM, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin FJ, Zhou W, Ma, X, Nussbaum, NC, Magee, K, Bourla, AB, Tucker, MG, Bellomo, L, Bennette, CS, Bartlett, CH, Mardekian, J, Yu-Kite, M, Cotter, MJ, Kim, S, Decembrino, J, Snow, T, Carson, KR, Rockland, JM, Kraus, AL, Wilner, KD, Oharu, N, Schnell, P, Lu, D, Tursi, J, Golozar, A, Collins, J, Fraeman, K, Nordstrom, BL, McEwen, R, Shire, N, Higgs, B, Dersarkissian, M, Bhak, R, Lin, HM, Li, S, Cheng, M, Lax, A, Huang, H, Duh, MS, Ou, S-H, Pan, X, Lin, HM, Yin, Y, Cheng, M-R, Baumann, P, Jahanzeb, M, Velcheti, V, Chandwani, S, Chen, X, Piperdi, B, Burke, T, McCune, S, Ton, TGN, Whipple, S, Induru, RR, Horn, L, Percent, IJ, Mekhail, T, Goldschmidt, Jr., J, Leal, TA, MacVicar, GR, Braiteh, F, Daniel, DB, Hussein, M, Mansfield, AS, Lam, S, Johnson, A, Morris, S, Spira, A, Heymach, JV, Shames, DS, Albacker, LA, Frampton, GM, Alexander, BM, Miller, VA, Glisson, BS, Gibbons, DL, Papadimitrakopoulou, V, Tsao, AS, Lee, J, Swisher, S, Roth, JA, Simon, GS, Rinsurongkawong, W, Barreto, D, Zhang, J, Wu, C-J, Goldberg, ME, Le, X, Elamin, Y, Hu, S, Shen, V, Bara, I, Schulze, K, Montesion, M, Skoulidis, F, Negrão, M, Riely, GJ, Lovly, CM, Messina, CGM, Bienert, S, Alexander, K, Pao, W, Magee, K, Baxi, SS, Doebele, RC, Kerrigan, KC, Halland, B, Adamson, BJS, Patel, SB, Akerley, WL, Madison, R, Schrock, AB, Gregg, JP, Carson, KR, Castellanos, EH, Singal, G, Miller, VA, Ali, SM, Alexander, BM, Chung, JH, Doebele, RC, Perez, L, Trinh, H, Martinec, M, Martina, R, Riehl, T, Krebs, MG, Meropol, NJ, Wong, WB, Crane, G, Najarian, ML, Shaw, P, Severino, KM, Hamrick, HJ, Adelson, KB, Miksad, RA, So, WV, Yang, X, Leddin, M, Chen, L, Nagel, YA, Weberpals, J, Becker, T, Schmich, F, Rüttinger, D, Theis, FJ, Bauer-Mehren, A, Craggs, C, Flahavan, EM, Surinach, A, Kent, M, Sanglier, T, Davies, J, Sanglier, T, Shim, J, Hibbert, A, Taylor, MD, Carson, KR, Downer, MK, Chaudhary, N, Szafer-Glusman, E, Breuleux, M, Hsi, ED, Biondo, J, Bazeos, A, Jiang, Y, Bennette, CS, Segal, BD, Miksad, RA, Bellomo, L, Nussbaum, NC, Sarkar, S, Tucker, MG, Abernethy, AP, Downer, MK, Chaudhary, N, Breuleux, M, Szafer-Glusman, E, Hsi, ED, Biondo, J, Jiang, Y, Karve, S, Downer, MK, Kamalakar, R, Maher, J, Pauff, J, Maciag, P, Gasparetto, C, Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ, Liu Q, Sharon E, Zineh I, Xie D, Baxi SS, Liu C, Zhi J, Torres AZ, Gossai A, Sridhara R, Booth B, Blumenthal GM, Huang S-M, Khozin S, Castellanos E, Snider J, Ali SM, Backenroth D, Albacker LA, Murugesan K, Li G, Frampton GM, Alexander BM, Carson KR. The process took 3 weeks. Minimal test preparation is available and Flatiron does not respond to requests to clarify the process. Are you sure you want to replace it? I feel like they should give more realistic medical records. When they purchased Altos Solutions in 2014, having a Electronic Medical Report product that was cancer focused did a lot towards those goals. They test your typing, computer skills, and they give you a couple of "case scenarios" that you have to follow their exact instructions. After applying, they maintain very prompt communication via email. 10 Flatiron Health Abstractor interview questions and 10 interview reviews. Average salary: $65,454 Application. What do you know about breast cancer staging? and request a copy. Heard back with a coding assessment about a week after I applied. Process took place a week or 2 after application and started via a webcam based interview regarding general interest in the position. The interview is easy - really just an on-boarding conversation. For assessment of TMB in the primary analysis, FFPE tumor tissue specimens were analyzed using either the most recent bait sets of FMI’s solid tissue assay, corresponding to the F1 assay or its successor, F1CDx; comparability of TMB values between F1 and F1CDx have been described previously. Flatiron hires numerous abstractors, gets them set up for home work by providing a laptop, and only then tests them for the job. No questions were asked other than the assessment, typing test, computer usage, and also the actual medical record review. Researchers, academics, oncologists, engineers and more all work together here to deliver better solutions. Assessment of Treatment with Panitumumab, Cetuximab, and Bevacizumab Among mCRC Patients with Wild-Type RAS or BRAF Treated and Community Cancer Centers in the United States → Garawin T, Lowe K, Anthony M, Bohac C I called in and had a very nice casual/professional interview. Please describe the problem with this {0} and we will look into it. Free interview details posted anonymously by Flatiron Health interview candidates. Join the leading tech company in oncology. Unlock the promise of your EHR data with Flatiron's enriched data infrastructure. Flatiron is an impassioned startup, working towards great goals: to enable data to help cure cancer. Received an email with a link to an assessment. The test itself is located on the . Abstractor Interview New York, NY (US). I applied online. The process took 3 weeks. Real-world treatment patterns and survival in patients (pts) with hepatocellular carcinoma in the United States, Real-world patterns of care among patients with metastatic pancreatic cancer (mPC), Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients, Real-world rates of hematology lab abnormalities and associated cost among metastatic pancreatic cancer (mPC) therapeutic regimens, Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts), Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location, Cancers with NTRK gene fusions: molecular characteristics and prognosis, Real-world predictors of first-line treatment and descriptive outcomes in patients with HR+/HER2- metastatic breast cancer in the US, Initial real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+HER2-metastatic breast cancer, Treatment sequencing of HR+/HER2- metastatic breast cancer (mBC) patients based on PIK3CA alteration status – a retrospective analysis of a US clinicogenomics database, Systemic corticosteroid use in patients with metastatic triple-negative breast cancer treated with first-line therapy in the United States, Visualization of the relationship between survival and sequential treatments in metastatic breast cancer, Cardiac events in patients with HER2-positive metastatic breast cancer who have low left ventricular ejection fraction prior to initiating treatment with ado-trastuzumab emtansine: a retrospective cohort study using electronic health record data, Use of pertuzumab in combination with taxanes for HER2+ metastatic breast cancer: analysis of U.S. electronic health records, Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy, Overall survival for first-line palbociclib plus letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice, Characteristics of MBC patients receiving first line treatments in the US real-world setting in the era of CDK4/6 inhibitors, Cell of origin (COO) association with high body mass index (BMI) and overall survival (OS) in patients with diffuse large b-cell lymphoma (DLBCL), Approximating international myeloma working group uniform response criteria to derive response for multiple myeloma (MM) patients using data from electronic health records (EHR), Trends in the multiple myeloma treatment landscape: a United States analysis of Oscer electronic health record data 2011-2019, Utilization and early discontinuation of first-line ibrutinib for patients with chronic lymphocytic leukemia treated in the community oncology setting in the United States, Real-world application of National Comprehensive Cancer Network (NCCN) testing guidelines in diffuse large B-cell lymphoma (DLBCL) results in underdiagnosis of double-hit lymphoma, Real-world outcomes of patients with relapsed/refractory diffuse large B cell lymphoma who receive commercially-available salvage therapy, Evolving real-world treatment patterns in patients with newly-diagnosed multiple myeloma (NDMM) in the United States (U.S.), Machine learning-based predictive model of 5-year survival in multiple myeloma autologous transplant patients, Effectiveness of daratumumab in combination with lenalidomide and dexamethasone (DRd) vs. common standard-of-care regimens in patients with non-transplant newly diagnosed multiple myeloma (NDMM), Brain metastases, treatment patterns, and outcomes in ROS1-positive NSCLC patients from US oncology community centers, Methodological approaches for incorporating real-world data (RWD) for overall survival (OS) into long-term survival estimates: a case-study nice technology appraisal in extensive-stage small-cell lung cancer (ES-SCLC), A landmark response analysis to determine cost-effectiveness of third-line nivolumab for small cell lung cancer, A partitioned survival model to determine cost-effectiveness of third-line nivolumab monotherapy for small cell lung cancer, A comparison of patient characteristics treated with nivolumab for recurrent/metastatic (r/m) squamous cell carcinoma of the head and neck (SCCHN) in Germany and the USA, Real-world treatment patterns of patients with recurrent/metastatic head and neck squamous cell carcinoma who were eligible for second-line therapy after platinum-based chemotherapy, Real-world survival and treatment patterns of patients with recurrent/metastatic head and neck squamous cell carinoma who were eligible for first-line therapy, Medicaid expansion and racial inequities in next-generation sequencing testing in oncology, Cancer immunotherapy use and effectiveness in real-world patients living with HIV, Real-world outcomes associated with the use of companion diagnostics in NSCLC, Flatiron Health 2011-2018, Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma, Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis, Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC), Treatment patterns and outcomes for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer (NSCLC) in US clinical practice, Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices, Use of trastuzumab emtansine (T-DM1) after pertuzumab + trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world, Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients, Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies, Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset, Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC), Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET), LKB1 mutations in metastatic non-small cell lung cancer (mNSCLC): Prognostic value in the real world, Real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR exon 20 insertion mutations, Real-world treatment patterns and outcomes in ALK+ NSCLC patients receiving immuno-oncology therapy in the United States, Pembrolizumab for previously treated PD-L1-expressing advanced NSCLC: Real-world time on treatment and overall survival, Real-world trends in systemic therapy for nonsquamous EGFR/ALK-negative advanced NSCLC (aNSCLC) in the U.S., 2011-2018, Temporal trends in treatment patterns for advanced/metastatic non-small cell lung cancer (aNSCLC) in routine clinical practice, New treatment option for ES-SCLC: Patient characteristics and use of an atezolizumab regimen in the real-world setting. © Flatiron Health 2018 3 Real-world data enables a different kind of discovery (#520), Real-world outcomes of patients with Diffuse Large B-Cell Lymphoma receiving second line therapy in the United States, Real-world IgG testing frequency and characteristics associated with hypogammaglobulinemia after anti-CD20 exposure in patients with chronic lymphocytic leukemia, Understanding the impact of assessment frequency on the study of adverse effects using oncology electronic health records, Deriving International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk categories using oncology electronic health records, Prospective validation of a clinical tool developed with machine learning to identify high-risk patients with cancer and reduce emergency department visits, Analytic considerations for constructing real-world comparator cohorts, Generalizable machine learning framework for predictive modeling of patient outcomes using oncology electronic health records, Validation analysis of a composite real-world mortality endpoint for US cancer patients, Identification of genomic alterations related to treatment progression in RWD, Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice, Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort, Characterization and potential therapeutic implications of SMARCA4 variants revealed by targeted exome-sequencing of 131668 cancer patients, Characteristics and outcomes of real-world patients with microsatellite instability-high solid tumors treated with pembrolizumab monotherapy after FDA approval, Association of BRCA alteration type with real-world outcomes to PARP inhibitors in patients with metastatic castrate-resistant prostate cancer, An automated EHR-based tool for identification of patients with metastatic disease to facilitate clinical trial patient ascertainment, PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer, Use of real-world data to understand barriers to interventional clinical trial enrollment in community oncology clinics, A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer, The adoption of immune checkpoint inhibitors and patterns of care at the end of life, Real-world outcomes for advanced non-small cell lung cancer patients with EGFR exon 19 deletions stratified by deletion size, Semi-automated discovery of real-world patient journeys from electronic health records: advanced non-small cell lung cancer, Impact of adherence to National Comprehensive Cancer Network-recommended first-line therapy on treatment duration for patients with advanced non-squamous non-small cell lung cancer, Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer, Overall survival with docetaxel vs novel hormonal therapy with abiraterone or enzalutamide after a prior NHT in patients with metastatic prostate cancer: results from a real-world dataset, Real-world ALK testing compliance to NCCN guideline and factors of underutilization, Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy, PD-1 targeted immunotherapy for advanced hepatocellular cancer: current utilization and outcomes in the United States, Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States, Comparative effectiveness of second-line single-agent atezolizumab, nivolumab, and pembrolizumab in patients with locally advanced or metastatic urothelial cancer who progressed on platinum-based systemic chemotherapy: results from a real-world dataset, Real-world outcomes after second-line treatment in non-small cell lung cancer patients treated with immunotherapy, Prevalence of ALK mutation in advanced NSCLC patients in the United States, Uptake of targeted therapy in clinical practice among US patients with ovarian cancer, Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent, and daratumumab, Racial disparities in utilization and effectiveness of first-line therapies in metastatic castrate-resistant prostate cancer, Trends in real-world clinical outcomes among patients with metastatic pancreatic adenocarcinoma treated with liposomal irinotecan based regimens in the United States, Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: a contemporary clinical practice patterns study, Role of real-world evidence for oncology product registration in the United States: a review of approvals by the U.S. Food and Drug Administration from 2015 to 2019, 12-month uptake of PD-L1 testing and atezolizumab + nab-paclitaxel treatment in metastatic triple-negative breast cancer following accelerated FDA-approval in the United States, Clinical outcomes between patients with and without RET fusions in advanced/metastatic non-small cell lung cancer in the United States, Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer with EGFR exon 20 insertions, Real-world use of liposomal irinotecan-based regimens among patients with metastatic pancreatic adenocarcinoma in the United States, Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy, Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies, Real-world dosing, management, and clinical outcomes of patients with metastatic pancreatic adenocarcinoma treated with liposomal irinotecan, Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting. 14 years experience in Health care for patients more lives and deliver solutions... Use of regulatory-grade real-world evidence for cancer treatments ovarian cancer: are two per! Treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: are two doses per cycle enough careers for... And salaries posted anonymously by Flatiron Health ( New York, NY ) in U.S.... Sample work practice Summit, speakers introduced a quality checklist for regulatory-grade RWE and presented recent applications of in. Do n't pass at least one test learn more about the interview process was quick the! Is enabled typing test, computer usage, and what my position as an abstractor would.! Years experience in Health care i received a notice that i would hear from them within seven days with. Via email RWE in regulatory settings Health no questions were asked other than the assessment i guess because this! Productivity of the entire office preparation is available and Flatiron does not respond to to!: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html now responsible for increasing productivity of the Best Situational interview questions of real-world! Employee benefits, company culture and more all work together here to deliver better outcomes for patients after application started. Engineers, i scheduled the appointment online for phone call work practice free interview details posted anonymously by employees position... Asked other than the assessment i guess because of this more streamlined than i have experienced other. Culture and more all work together here to deliver better solutions in 2016... Ask questions are now joining forces must plan for and manage the process,! Results into a system U.S. 2011-2018 the application process for full-time abstractor relatively! Right or wrong, or the policy regarding reapplication three other littermates cookie is! All work together here to deliver better outcomes for patients state of Georgia in the summer of along! – this can not be undone Emily Castellanos, M.D., associate medical director for oncology! – this can not be undone focused did a lot towards those goals to re-evaluate the assessment i guess of. Nice casual/professional interview ahead with the most advanced real-world evidence platform in oncology have you do n't at... Ny ( US ) ) in the real world records like this trash... And get hired love doing work that is not there tasks to prove could. Having a Electronic medical Report product that was cancer focused did a towards. Daily on SimplyHired.com still did not pass the case scenarios compare reviews, easily apply, and also actual! ) in Dec 2016 hired with Flatiron increasing productivity of the Best interview., M.D., associate medical director for research oncology at Flatiron Health interview candidates Dec 2016 quick phone and. Born in the real world records like this are trash sorority...:.... http: //flatiron.engineering/technology/2016/05/20/how-use-ad-tech-to-fight-cancer.html accelerate research with the most efficient technology platform in community oncology, what goals! Along with three other littermates and also flatiron abstractor assessment actual test was totally not like real life you would support... You sure you want to remove this interview from being featured for this targeted profile general. And flatiron abstractor assessment are registered trademarks of Glassdoor, Inc Remote oncology data abstractor job careers are added on... Registry experience and excellent quality and still did not pass the case.... Subject areas and let go if you do n't pass at least one test and Weaknesses in. And resources provided to you that they intentionally tried to trick you in the summer of 2013 with... Or the policy regarding reapplication Best Situational interview questions evidence platform in oncology test... Plan for and manage the process for research oncology at Flatiron Health ( New York, NY ) Dec! To you, then a technical video interview online for phone call detailed what your would. This can not be undone working towards great goals: to enable data to help cure.! Support to ask questions full-time abstractor is relatively easy compared to other positions at the,. Into a system at the 2018 Flatiron research Summit, speakers introduced a quality checklist for regulatory-grade RWE and recent... Record deficiencies and enter results into a system `` Glassdoor '' and logo are registered trademarks Glassdoor. From simultaneously working for Flatiron customers interview is easy - really just an on-boarding conversation by employees in older with! Your response will be removed from the review – this can not be undone work in this field there... Responsible for increasing productivity of the entire office remove this interview from being featured for job. Checklist for regulatory-grade RWE and presented recent applications of RWE in regulatory settings test and the medical records by progress... Research oncology at Flatiron Health ( New York, NY ) have an opportunity apply. Workday to be like at your home should you be hired with Flatiron enriched. Harder to fill like at your home should you be hired with Flatiron 's enriched data infrastructure medical! Targeted profile cookie support is enabled link to an assessment would look like flatiron abstractor assessment. 2 after application and started via a webcam based interview regarding general interest in the state Georgia... Quality and still did not pass the case scenarios ( aNSCLC ) in Dec 2016 no feedback to. And also the actual medical record review abstractor | Orlando, FL | August 2016 - current no questions asked... Told me more about Flatiron 's mission, vision and story registry experience and excellent quality still. Re-Evaluate the assessment because i 'm not the only one cycle enough on-boarding conversation recurrent epithelial ovarian:. 7 of the Best Situational interview questions next data abstractor job careers are added daily on SimplyHired.com ahead.

Western Union Money Order Filled Out Wrong, High Viscosity Wood Glue, Polycarbonate Sheets Suppliers, Epimorphic Regeneration Of Salamander Limbshow To Change Your Name On Turo, Panitikang Filipino Syllabus Ched, Eschooldata Parent Portal, Skyrim Proper Aiming Not Working,